Current Status and Future Perspective of Stenting for Symptomatic Intracranial Atherosclerotic Disease: A Meta-Analysis

Table 2

Characteristics of the trails mentioned in the Discussion.

Author/year	Cases	Trail detail	Eligible patients	Stenosis (% mean ± SD)	Stenosis location	Stent type	Any stroke and death at 30 days (%)
Jiang et al./2012	637	Multicenter retrospective study of consecutive patients	Symptomatic ICAD		Intracranial ICA, MCA, BA, intradural VA	BES or SES	6.1
Miao et al./2015	158	Single center prospective cohort study	Symptomatic ICAD caused by hypoperfusion combined with poor collateral flow		Intracranial ICA, MCA, BA, intradural VA	BES for smooth access and Mori A lesion, SES for tortuous access and Mori B or C lesion, and angioplasty alone for tortuous access and Mori A lesion	4.4
Li et al./2015	433	Single center prospective study of consecutive patients	Over 24 hours from the final TIA event and over 7 days from the final stroke caused by ICAD		Intracranial ICA, MCA, BA, intradural VA	SES	6.7
Miao et al./2015	300	Multicenter prospective single-arm registry study	Symptomatic ICAD combined with poor collaterals and acute infarcts within 3 weeks were excluded		Intracranial ICA, MCA, BA, intradural VA	BES or SES	4.3
Gao et al./2016	100	Multicenter prospective single-arm trial	TIA or ischemic stroke caused by ICAD and ischemic symptoms within 3 weeks were excluded		Intracranial ICA, MCA, BA, intradural VA	SES	2

SD, standard deviation; ICAD, intracranial atherosclerotic disease; MCA, middle cerebral artery; VA, vertebral artery; ICA, internal carotid artery; BA, basilar artery BES, balloon-expandable stent; SES: self-expanding stent; TIA transient ischemic attack.